Drugs In Development for Binge Eating Disorders: 2021 Pipeline Guide – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Binge Eating Disorder (Central Nervous System) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
The pipeline guide provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Binge Eating Disorder pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6 and 1 respectively.
The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder
Companies Mentioned
- Amygdala Neurosciences Inc
- Bright Minds Biosciences Inc
- Chronos Therapeutics Ltd
- F. Hoffmann-La Roche Ltd
- Idorsia Pharmaceutical Ltd
- Omeros Corp
- OXonium Therapeutics
- Seropeutics LLC
- Vivus Inc
- Yichang Renfu Pharmaceutical Co Ltd
Key Topics Covered:
Introduction
Binge Eating Disorder – Overview
- Binge Eating Disorder – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Binge Eating Disorder – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Binge Eating Disorder – Companies Involved in Therapeutics Development
- Amygdala Neurosciences Inc
- Bright Minds Biosciences Inc
- Chronos Therapeutics Ltd
- F. Hoffmann-La Roche Ltd
- Idorsia Pharmaceutical Ltd
- Omeros Corp
- OXonium Therapeutics
- Seropeutics LLC
- Vivus Inc
- Yichang Renfu Pharmaceutical Co Ltd
Binge Eating Disorder – Drug Profiles
- (phentermine hydrochloride + topiramate) ER – Drug Profile
- ACT-539313 – Drug Profile
- ANS-6637 – Drug Profile
- CT-010018 – Drug Profile
- CTDP-002 – Drug Profile
- Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder – Drug Profile
- lisdexamphetamine dimesylate – Drug Profile
- OMS-527 – Drug Profile
- RO-5256390 – Drug Profile
- SERx-480 – Drug Profile
- Small Molecules to Agonize 5 HT2C for Neurology and Psychiatric Disorders – Drug Profile
Binge Eating Disorder – Dormant Projects
Binge Eating Disorder – Discontinued Products
Binge Eating Disorder – Product Development Milestones
Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/r/mjngd0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
